Gland Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021
January 21, 2022 at 05:11 am EST
Share
Gland Pharma Limited reported earnings results for the third quarter and nine months ended December 31, 2021. For the third quarter, the company reported sales was INR 10,633.25 million compared to INR 8,594.19 million a year ago. Revenue was INR 11,089.94 million compared to INR 8,945.49 million a year ago. Net income was INR 2,730.29 million compared to INR 2,041.07 million a year ago. Basic earnings per share from continuing operations was INR 16.62 compared to INR 12.83 a year ago. Diluted earnings per share from continuing operations was INR 16.62 compared to INR 12.82 a year ago.
For the nine months, sales was INR 32,976.94 million compared to INR 25,751.28 million a year ago. Revenue was INR 34,563.98 million compared to INR 26,626.9 million a year ago. Net income was INR 9,257.62 million compared to INR 7,365.54 million a year ago. Basic earnings per share from continuing operations was INR 56.41 compared to INR 47.12 a year ago. Diluted earnings per share from continuing operations was INR 56.41 compared to INR 47.1 a year ago.
Gland Pharma Limited is an India-based generic injectables manufacturer. The Company specializes in sterile injectables, oncology, and ophthalmic, with a specific focus on complex injectables, NCE-1s (New Chemical Entities), First-to-File products, and 505(b)(2) filings. The Company functions primarily on a business-to-business (B2B) model and has a record in pharmaceutical research and development, manufacturing, and marketing of complex injectables. The Company offers a range of delivery systems, including liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops. It is also in the process of including new delivery systems such as pens and cartridges into its product portfolio. Its key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Gynaecological, Hormones, and others.
GLAND PHARMA LIMITED 
